Copper Cu 64 dotatate
The copper-64 version of the neuroendocrine tumour PET scan
Copper Cu 64 dotatate is the somatostatin analogue octreotate, linked to a DOTA chelator and labelled with copper-64. Like the gallium version it binds somatostatin receptors for PET imaging of neuroendocrine tumours; copper-64's longer life means it is supplied ready to inject. FDA approved it as Detectnet in 2020.
Manufacturer's recommended dosing (FDA label): 148 MBq (4 mCi), Single injection over about 1 minute, Intravenous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Copper Cu 64 dotatate uses the same receptor-targeting peptide as the gallium-68 scan with a different radioactive label. Copper-64 lasts much longer than gallium-68, so the product can be made centrally and shipped ready to use instead of being prepared on site from a generator, and the label sets imaging 45 to 90 minutes after injection.
In its phase 3 study, a dose-ranging part set 148 MBq as the optimal dose, and masked readers then achieved 90.9% sensitivity and 96.6% specificity in 63 people (100% and 96.8% after a standard-of-truth correction), with no drug-related adverse events. In a head-to-head study of 59 patients, it found 33 true-positive lesions that gallium-68 DOTATOC missed, against 7 the other way. Earlier, in a prospective comparison of 112 patients, it was more sensitive than indium-111 octreotide SPECT (97% against 87%) and found twice as many lesions.
The longer half-life buys flexibility. In 35 patients scanned at both 1 and 3 hours, almost every lesion appeared on both, so a delay in the scanner schedule does not cost diagnostic yield. The activity can probably be lowered: simulated scans at about 142 MBq kept image quality and detection, which matters for radiation dose in patients scanned repeatedly.
How brightly a tumour lights up carries information. In 128 patients followed for about six years, high uptake predicted slower progression but not survival, with only moderate accuracy. A 116-patient analysis did better by combining total tumour volume with the uptake of the least avid lesion: patients with low volume and high minimum uptake had a hazard ratio for death of 0.24 against the comparison group.
It is not specific to cancer, and shortcuts have limits. A benign lung hamartoma took it up because its vessel and muscle cells carry somatostatin receptors. AI-denoised quarter-dose scans looked like full-dose ones but missed a third of lesions and invented others.
Because activated macrophages also carry somatostatin receptors, researchers have used it to image inflamed artery walls: uptake tracked cardiovascular risk scores and was higher in carotid plaques that had caused symptoms, a research use outside the label.
The label lists radiation risk, hypersensitivity reactions and a risk of image misinterpretation. It is approved for adults, at 148 MBq given over about a minute and used within 2 hours of calibration. Because it is supplied ready to inject, sites without a gallium-68 generator can still offer somatostatin receptor PET.
Mechanism of Action
Copper-64 dotatate carries a longer-lived positron emitter to somatostatin receptors, so neuroendocrine tumours show on PET.
Somatostatin receptors
Dotatate binds somatostatin receptors, mainly subtype 2; maximum activity is seen in adrenals, kidneys, pituitary, spleen and liver at 1 to 3 hours (label 12.3).
Copper-64 positrons
Copper-64's longer half-life lets the dose be made centrally and shipped ready to inject.
Urinary excretion
Between 16% and 40% of the dose is recovered in urine within 6 hours (label 12.3).
Published Research
Studies of copper-64 dotatate, from their PubMed abstracts.
Phase 3: dose and diagnostic performance
A dose-ranging study chose 148 MBq; masked reads of 21 healthy volunteers and 42 patients gave 90.9% sensitivity and 96.6% specificity (100% and 96.8% after correcting a standard-of-truth misread), with no drug-related or serious adverse events.
Head-to-head against gallium-68 DOTATOC
In 59 patients, 701 lesions were found by both scans; of 68 found by only one, copper-64 DOTATATE found 33 true positives and gallium-68 DOTATOC 7, so 83% of additional true lesions came from the copper tracer.
First in humans
In 14 patients, copper-64 DOTATATE PET gave high-quality images with stable tumour-to-background ratios for at least 3 hours and found additional lesions in 6 (43%) compared with conventional scintigraphy, including previously unknown metastatic sites.
Against indium-111 octreotide SPECT
In 112 patients, sensitivity and accuracy were 97% for copper-64 DOTATATE against 87% and 88% for indium-111 octreotide; PET found more lesions in 75% of patients and twice as many lesions overall, with no SPECT-positive case missed by PET.
Uptake in arteries and cardiovascular risk
In 60 patients with neuroendocrine tumours scanned with both tracers, copper-64 dotatate showed higher uptake than gallium-68 DOTATOC in large arteries, and its uptake correlated with Framingham risk score (r = 0.4), which gallium-68 DOTATOC uptake did not.
Inflamed carotid plaques
In 10 patients before carotid endarterectomy, copper-64 dotatate PET/MRI uptake was higher in the symptomatic plaque than in the opposite carotid artery, and tracked markers of activated macrophages in the removed tissue. This research use is not on the label.
Imaging at 1 hour or 3 hours
In 35 patients scanned 1 and 3 hours after 200 MBq, 822 lesions were seen on both and only 5 on one; lesion counts did not differ and tumour-to-background ratios stayed high, so the imaging window is flexible.
Uptake and outcome
In 128 patients followed for a median 73 months, a maximum tumour uptake (SUVmax) above 43.3 predicted longer progression-free survival (adjusted hazard ratio 0.50) but not overall survival, with moderate accuracy.
A lower activity still works
Re-reading scans with simulated lower activity, the dose could fall from a median 191 MBq to 142 MBq without loss of image quality or lesion detection, and to 95 MBq without loss of clinically relevant information.
Tumour volume and the weakest lesion
In 116 patients, total tumour volume and the uptake of the least avid lesion both predicted progression and survival; those with low volume and high minimum uptake had hazard ratios of 0.32 for progression and 0.24 for death.
AI denoising of quarter-dose scans
In 33 patients, AI-denoised quarter-dose scans looked like full-dose ones, but only 66% of true lesions were found and 32% of reported lesions were false, so image quality did not equal diagnostic accuracy.
A benign lung nodule that lit up
Case report: a slowly growing lung nodule suspected to be carcinoid took up copper-64 dotatate but was a hamartoma, whose blood vessel and smooth muscle cells expressed somatostatin receptor 2.
Dosing Data
Detectnet is a single ready-to-use intravenous dose given in a nuclear medicine department, with PET imaging 45 to 90 minutes later.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Detectnet (copper cu 64 dotatate injection): Injection: 148 MBq (4 mCi) (37 MBq (1 mCi) per 1 mL) of copper Cu 64 dotatate in a single-dose vial. Forms the label lists: single-dose vials.
Source: Detectnet (copper cu 64 dotatate injection) label, section 3 (DailyMed version 5, effective January 31, 2025).
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Copper Cu 64 dotatate is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.
This page's dosing note: “Radioactive diagnostic agent given only by nuclear medicine staff; used within 2 hours of its calibration time.”
Its label says: “Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.”
Source: this page's own note in Dosing Data below; Detectnet (copper cu 64 dotatate injection) label, section 2 (DailyMed version 5, effective January 31, 2025); the amount of each dose row in Dosing Data below.
Storage before and after mixing
Before mixing or first use: “Store Detectnet in an upright position within the lead shielding to protect handlers from exposure to radiation.” “Store Detectnet at controlled room temperature 20 ° C to 25 ° C (68 ° F to 77 ° F).” “Store and dispose of Detectnet in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.”
After mixing or first use: “Discard unused portion from the single-patient use vial.”
Source: Detectnet (copper cu 64 dotatate injection) label, sections 16 and 2 (DailyMed version 5, effective January 31, 2025).
How it is taken
As the approved label gives it: Intravenous (Single injection over about 1 minute; Label: PET localisation of somatostatin receptor-positive neuroendocrine tumours, adults).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Label: PET localisation of somatostatin receptor-positive neuroendocrine tumours, adults: Imaging 45-90 minutes after injection.
When effects appear: unknown; no source on this page gives a time to effect for Copper Cu 64 dotatate. Results reported in the studies are under Published Research.
Source: Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: No drug-related adverse events in the phase 3 study. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Copper Cu 64 dotatate. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- long-acting somatostatin analogues: compete for receptors; a 28-day washout is recommended before imaging
- short-acting somatostatin analogues: compete for receptors; a 2-day washout is recommended before imaging
Every peptide's record, with its source: the interaction matrix.
Source: Curium. DETECTNET (copper Cu 64 dotatate) US prescribing information, section 7. DailyMed version of January 31, 2025, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Copper Cu 64 dotatate products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Detectnet (copper Cu 64 dotatate injection), NDA 213227, on September 3, 2020 (Drugs@FDA via openFDA and the Detectnet label effective January 31, 2025, read October 3, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Detectnet label (DailyMed, effective January 31, 2025).
Legal Status
Copper Cu 64 dotatate is an approved prescription diagnostic in the US.
Frequently Asked Questions
?How is copper-64 dotatate different from gallium-68 dotatate?
Both use the same octreotate peptide; copper-64 lasts longer, so the product is shipped ready to inject. In one head-to-head study it detected more true-positive lesions than a gallium-68 tracer.
?How accurate is the Detectnet scan?
In its phase 3 study, masked readers achieved 90.9% sensitivity and 96.6% specificity, rising to 100% and 96.8% after a reference-standard correction.
?When are images taken?
The label says to begin imaging 45 to 90 minutes after the injection.
?Is it better than the older octreotide scan?
Yes, in a 112-patient prospective comparison: sensitivity and accuracy were 97% for copper-64 DOTATATE against 87% and 88% for indium-111 octreotide SPECT, and PET found twice as many lesions.
?How long do the images stay usable?
In the first human study, tumour-to-background ratios stayed high and stable for at least three hours after injection, which gives imaging centres flexibility; the label itself sets imaging at 45 to 90 minutes.
?Who can have a Detectnet scan?
The label approves it for adults with known or suspected somatostatin receptor-positive neuroendocrine tumours; the gallium-68 version is also approved for children.
References
- [fda] US FDA, Drugs@FDA (openFDA): DETECTNET, NDA 213227 (September 3, 2020). Read October 3, 2026.
- [fda-pi] FDA. Detectnet (copper Cu 64 dotatate) US prescribing information (DailyMed set f898c8a7-beb7-4318-a8ea-6f058d69342b, version 5, effective January 31, 2025). Read October 3, 2026.
- [clinical-trial] Delpassand ES, et al. "(64)Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial." J Nucl Med, 2020;61(6):890-896. PMID: 31924723.
- [pubmed] Johnbeck CB, et al. "Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors." J Nucl Med, 2017;58(3):451-457. PMID: 27660147.
- [pubmed] Pfeifer A, et al. "Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study." J Nucl Med, 2012;53(8):1207-15. PMID: 22782315.
- [pubmed] Pfeifer A, et al. "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients." J Nucl Med, 2015;56(6):847-54. PMID: 25952736.
- [pubmed] Malmberg C, et al. "64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients." J Nucl Med, 2015;56(12):1895-900. PMID: 26429961.
- [pubmed] Pedersen SF, et al. "64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy." Arterioscler Thromb Vasc Biol, 2015;35(7):1696-703. PMID: 25977567.
- [pubmed] Loft M, et al. "(64)Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection." J Nucl Med, 2021;62(1):73-80. PMID: 32444370.
- [pubmed] Carlsen EA, et al. "(64)Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms." J Nucl Med, 2020;61(10):1491-1497. PMID: 32111685.
- [pubmed] Loft M, et al. "Activity Dose Reduction in (64)Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability." Mol Imaging Biol, 2022;24(4):600-611. PMID: 35167028.
- [fda-pi] Detectnet (copper Cu 64 dotatate injection) US prescribing information (Curium; DailyMed set f898c8a7, version 5, effective January 31, 2025), sections 2.2, 2.4 and 12.3; read through openFDA October 6, 2026.
- [pubmed] Carlsen EA, et al. "Semiautomatic Tumor Delineation for Evaluation of (64)Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume." J Nucl Med, 2021;62(11):1564-1570. PMID: 33637589.
- [pubmed] Loft M, et al. "An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose (64)Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms." J Nucl Med, 2023;64(6):951-959. PMID: 37169532.
- [pubmed] Song H, et al. "64Cu-DOTATATE Uptake in a Pulmonary Hamartoma." Clin Nucl Med, 2023;48(1):58-60. PMID: 36469060.
Sources & Citations
Studies were read from their PubMed abstracts; the Detectnet label from DailyMed (set f898c8a7, effective January 31, 2025) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.